Phase 1, Randomized, Double-Blind, Pharmacokinetic and Glucodynamic 6-Way Crossover Study of SC Administered Insulin Lispro With Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin With Recombinant Human Hyaluronidase (rHuPH20) Compared to Insulin Lispro Alone in Healthy Volunteers

Trial Profile

Phase 1, Randomized, Double-Blind, Pharmacokinetic and Glucodynamic 6-Way Crossover Study of SC Administered Insulin Lispro With Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin With Recombinant Human Hyaluronidase (rHuPH20) Compared to Insulin Lispro Alone in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2014

At a glance

  • Drugs Hyaluronidase; Insulin; Insulin lispro
  • Indications Diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Halozyme Therapeutics
  • Most Recent Events

    • 07 Nov 2009 Study results were presented the Diabetes Technology Society meeting, according to a Halozyme media release.
    • 06 Oct 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
    • 06 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top